Gastrointestinal Adverse Reactions from Ibuprofen

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  2015-07-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/9781118743614.CH9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Gastrointestinal safety of NSAIDs and over‐the‐counter analgesics

  2013cited by this paper
• Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis.

  2013cited by this paper
• Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR)

  2012cited by this paper
• Small bowel injury induced by selective cyclooxygenase-2 inhibitors: a prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam

  2012cited by this paper
• In vitro and in vivo Protection against Indomethacin-Induced Small Intestinal Injury by Proton Pump Inhibitors, Acid Pump Antagonists, or Indomethacin-Phosphatidylcholine

  2012cited by this paper
• Nabumetone

  2012cited by this paper
• NSAIDs: take with food or after fasting?

  2012cited by this paper
• Editorial: Single-Tablet Ibuprofen/Double-Dose Famotidine for Reduction of Gastric and Duodenal Ulcers (REDUCE Trials): What Can be Reduced?

  2012cited by this paper
• NSAID-Mucosal Injury: Roles of Drug Chemistry in Pathogenesis

  2012cited by this paper
• HZT-501 (DUEXIS®; ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis

  2012cited by this paper
• Tolmetin: A Review of its Pharmacological Properties and Therapeutic Efficacy in Rheumatic Diseases

  2012cited by this paper
• Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events?

  2012cited by this paper
• Effect of Non-Steroidal Anti-Inflammatory Drugs on the Human Small Intestine

  2012cited by this paper
• Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: characterization of interaction of NSAIDs with phosphatidylcholine.

  2012cited by this paper
• Ibuprofen-phospholipid solid dispersions: improved dissolution and gastric tolerance.

  2012cited by this paper
• Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials

  2011cited by this paper
• Acute lower gastrointestinal bleeding management in Portugal: a multicentric prospective 1-year survey

  2011cited by this paper
• Epidemiology and role of nonsteroidal antiinflammatory drugs in causing gastrointestinal bleeding.

  2011cited by this paper
• Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers

  2011cited by this paper
• Rofecoxib and clinically significant gastrointestinal events.

  2011cited by this paper
• A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain

  2011cited by this paper
• Low-Dose Aspirin-Induced Ulceration Is Attenuated by Aspirin–Phosphatidylcholine: A Randomized Clinical Trial

  2011cited by this paper
• Fifty years since the discovery of ibuprofen

  2011cited by this paper
• A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: Results from two randomized, parallel-group, placebo-controlled trials

  2011cited by this paper
• Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: Two faces of the same coin

  2011cited by this paper
• Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.

  2011cited by this paper
• Rofecoxib and Clinically Significant Upper and Lower Gastrointestinal Events Revisited Based on Documents From Recent Litigation

  2011cited by this paper
• Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis

  2011cited by this paper
• Time-trends in gastroprotection with NSAIDs

  2010cited by this paper
• Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness

  2010cited by this paper
• Adverse effects of drugs on small intestine and colon.

  2010cited by this paper
• Impact of aspirin, NSAIDs, warfarin, corticosteroids and SSRIs on the site and outcome of non-variceal upper and lower gastrointestinal bleeding

  2010cited by this paper
• Time‐trends in gastroprotection with nonsteroidal anti‐inflammatory drugs (NSAIDs)

  2010cited by this paper
• Partitioning of nonsteroidal antiinflammatory drugs in lipid membranes: a molecular dynamics simulation study.

  2010cited by this paper
• Optimal Management of Peptic Ulcer Disease in the Elderly

  2010cited by this paper
• The comparative safety of analgesics in older adults with arthritis.

  2010cited by this paper
• Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention.

  2010cited by this paper
• Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

  2010cited by this paper
• Clinical trial: the incidence of NSAID‐associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric‐coated naproxen alone

  2010cited by this paper
• The relative toxicity of nonsteroidal antiinflammatory drugs.

  2010cited by this paper
• Ibuprofen: pharmacology, efficacy and safety

  2009cited by this paper
• Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use

  2009cited by this paper
• Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: benefits versus risks

  2009cited by this paper
• Intestinal permeability in the pathogenesis of NSAID-induced enteropathy

  2009cited by this paper
• Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm.

  2009cited by this paper
• Investigation of some factors contributing to negative food effects

  2009cited by this paper
• Time Trends and Impact of Upper and Lower Gastrointestinal Bleeding and Perforation in Clinical Practice

  2009cited by this paper
• Prevalence of fatal adverse drug reactions in hospitalized patients.

  2009cited by this paper
• Proton pump inhibitors for gastroduodenal damage related to nonsteroidal anti-inflammatory drugs or aspirin: twelve important questions for clinical practice.

  2009cited by this paper
• Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future.

  2009cited by this paper
• Guidelines for Prevention of NSAID-Related Ulcer Complications

  2009cited by this paper
• Preadmission use of SSRIs alone or in combination with NSAIDs and 30-day mortality after peptic ulcer bleeding

  2009cited by this paper
• Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action.

  2009cited by this paper
• Clarifying the Relationship Between ABO/Rhesus Blood Group Antigens and Upper Gastrointestinal Bleeding

  2009cited by this paper
• Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?

  2009cited by this paper
• Hospitalization for peptic ulcer and bleeding in users of selective COX‐2 inhibitors and nonselective NSAIDs with special reference to celecoxib

  2008cited by this paper
• Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: A Japanese multicenter study

  2008cited by this paper
• Epidemiology of acute upper gastrointestinal bleeding.

  2008cited by this paper
• Clinical trial: comparison of ibuprofen‐phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients

  2008cited by this paper
• Management of chronic musculoskeletal pain in the Elderly: Opinions on oral medication use

  2008cited by this paper
• The ADVANTAGE Seeding Trial: A Review of Internal Documents

  2008cited by this paper
• Prevalence, Clinical Features and Avoidability of Adverse Drug Reactions as Cause of Admission to a Geriatric Unit

  2008cited by this paper
• Hospitalization for gastrointestinal adverse events attributable to the use of low‐dose aspirin among patients 50 years or older also using non‐steroidal anti‐inflammatory drugs: a retrospective cohort study

  2007cited by this paper
• Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.

  2007cited by this paper
• Ibuprofen: A Journey from Prescription to Over-the-Counter Use

  2007cited by this paper
• Pharmacodynamic of cyclooxygenase inhibitors in humans.

  2007cited by this paper
• Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: A case-control study

  2007cited by this paper
• Clinical trial: healing of NSAID‐associated gastric ulcers in patients continuing NSAID therapy – a randomized study comparing ranitidine with esomeprazole

  2007cited by this paper
• Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?

  2007cited by this paper
• Adverse drug interactions involving common prescription and over-the-counter analgesic agents.

  2007cited by this paper
• Determinants of the short‐term gastric damage caused by NSAIDs in man

  2007cited by this paper
• Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.

  2007cited by this paper
• Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon.

  2007cited by this paper
• Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study.

  2007cited by this paper
• Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.

  2007cited by this paper
• Bleeding Peptic Ulcer in the Elderly

  2007cited by this paper
• NSAID-analgesia, pain control and morbidity in cardiothoracic surgery

  2006cited by this paper
• Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy?

  2006cited by this paper
• Intragastric acid control in non‐steroidal anti‐inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole

  2006cited by this paper
• Dose–effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects

  2006cited by this paper
• Effect of naproxen on gastric acid secretion and gastric pH

  2006cited by this paper
• Comparative Bioavailability Study of Two Ibuprofen Preparations after Oral Administration in Healthy Volunteers

  2006cited by this paper
• Response to expression of concern regarding VIGOR study.

  2006cited by this paper
• Gastrointestinal Complications of Over-the-Counter Nonsteroidal Antiinflammatory Drugs

  2006cited by this paper
• Risk of serious upper gastrointestinal toxicity with over-the-counter nonaspirin nonsteroidal anti-inflammatory drugs.

  2005cited by this paper
• A Nationwide Study of Mortality Associated with Hospital Admission Due to Severe Gastrointestinal Events and Those Associated with Nonsteroidal Antiinflammatory Drug Use

  2005cited by this paper
• A review of upper-gastrointestinal effects of the newer nonsteroidal antiinflammatory agents

  2005cited by this paper
• Adverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospital.

  2005cited by this paper
• Influence of moclobemide on ibuprofen-induced faecal blood loss

  2005cited by this paper
• Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

  2005cited by this paper
• A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy.

  2005cited by this paper
• Prospective study of acute gastrointestinal bleeding attributable to anti-inflammatory drug ingestion in the Yorkshire region of the United Kingdom

  2005cited by this paper
• Ibuprofen Extrudate, a Novel, Rapidly Dissolving Ibuprofen Formulation: Relative Bioavailability Compared to Ibuprofen Lysinate and Regular Ibuprofen, and Food Effect on All Formulations

  2005cited by this paper
• Effects of nonsteroidal antiinflammatory drugs on ulcerogenesis and gastric secretion in pylorus-ligated rat

  2005cited by this paper
• Pharmacokinetics of ibuprofen sodium dihydrate and gastrointestinal tolerability of short-term treatment with a novel, rapidly absorbed formulation.

  2005cited by this paper
• Visible small-intestinal mucosal injury in chronic NSAID users.

  2005cited by this paper
• The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis*

  2005cited by this paper
• Time course and pattern of blood loss with ibuprofen treatment in healthy subjects.

  2005cited by this paper
• Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

  2005cited by this paper
• The murky world of the COX-2-selective agents

  2005cited by this paper

• Chromium-based itaconic acid-functionalized MOF: a microcarrier for sustained drug release, synergistic antibacterial effect with metronidazole, and enhanced infection control

  2025cites this paper
• Gastrointestinal Complications of Antirheumatic Drugs

  2017cites this paper